WHO ICTRP trial
Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment…
CTIS2023-509088-26-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2023-509088-26-00 |
|---|---|
| Public title | Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study |
| Scientific title | Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study |
| Primary sponsor | Gruppo Oncologico Del Nord Ovest |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Italy |
| Conditions | Metastatic colorectal cancer;Therapeutic area: Diseases [C] - Digestive System Diseases [C06];Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: Erbitux 5 mg/mL solution for infusion, Product Code:PRD3702716, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Braftovi 75 mg hard capsules, Product Code:PRD6728382… |
| Registration date | Dec 3, 2024 |
| Target size | 16 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: